Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of dapagliflozin vs tocilizumab in systemic sclerosis
2025-523714-92-00Phase 2Withdrawn
- Sponsor
- Centrum Medyczne Kształcenia Podyplomowego
- Start
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing Dapagliflozin arm with Tocilizumab arm (2 arms). Primary endpoint: Change in disease severity assessed by modified Rodnan Skin Score (mRSS) at 12 months. Planned start Dec 2025; status: withdrawn.
02
Drugs
dapagliflozintocilizumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2025-523714-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523714-92-00.